Immutep Limited (IMMP)Healthcare | Biotechnology | Sydney, Australia | NasdaqGM
0.46 USD
+0.01
(1.776%)
⇧
(July 14, 2026, 9:31 a.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:05 a.m. EDT
The investment case for Immutep is currently overwhelmed by severe legal and operational headwinds. The company faces active securities fraud investigations alleging a failure to disclose risks regarding trial viability, coupled with a recent 80% share plunge after a lung cancer trial was halted. Fundamentally, the business is deteriorating with negative revenue growth, massive operating losses, and negative free cash flow. While the stock trades at a low multiple relative to book value, this appears to be a 'value trap' where the market has already priced in the potential for total capital loss due to the litigation and failed clinical programs. There is no reliable path to profitability visible in the current data, and the balance sheet, while liquid, is being drained by operations. The lack of dividends reflects the company's inability to generate surplus cash. Short-term momentum remains bearish, and the long-term outlook is precarious given the ongoing legal battles and halted research pipelines. |
| Model | MAE |
|---|---|
| MSTL_60_126 ✓ | 0.134836 |
| MSTL_126 | 0.168974 |
| MSTL_60 | 0.294318 |
| MSTL | 0.323814 |
| AutoETS | 0.358273 |
| AutoARIMA | 0.358274 |
| AutoTheta | 0.365853 |
Forecast horizon: 60 days | Selected: MSTL_60_126
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 0.07 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.252 |
| Excess Kurtosis | 0.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.223 |
| Revenue per Share | 0.05 |
| Market Cap | 67,570,120 |
| Forward P/E | -2.29 |
| Beta | 2.22 |
| Website | https://www.immutep.com |
As of July 11, 2026, 6:05 a.m. EDT: Speculators are positioning for a continued decline with heavy put buying at strikes significantly above the current price (OTM puts showing new flow at $5.00), while call activity is sparse and concentrated at lower strikes. Implied volatility is elevated relative to deep OTM strikes, suggesting fear of further downside rather than a rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7239264 |
| Address1 | Australia Square |
| Address2 | Level 32 264 George Street |
| All Time High | 25.5 |
| All Time Low | 0.29 |
| Ask | 0.5864 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 469,100 |
| Average Daily Volume3 Month | 13,759,327 |
| Average Volume | 13,759,327 |
| Average Volume10Days | 469,100 |
| Beta | 2.219 |
| Bid | 0.304 |
| Bid Size | 2 |
| Book Value | 0.464511 |
| City | Sydney |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Australia |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.4585 |
| Current Ratio | 2.973 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.459 |
| Day Low | 0.44 |
| Debt To Equity | 1.223 |
| Display Name | Immutep |
| Dividend Date | 1,482,883,200 |
| Earnings Timestamp End | 1,772,139,600 |
| Earnings Timestamp Start | 1,772,139,600 |
| Ebitda | -82,390,280 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.383 |
| Enterprise To Revenue | -3.98 |
| Enterprise Value | -31,528,748 |
| Eps Current Year | -0.32 |
| Eps Forward | -0.2 |
| Eps Trailing Twelve Months | -0.43 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 61 2 8569 1880 |
| Fifty Day Average | 0.4242 |
| Fifty Day Average Change | 0.0343 |
| Fifty Day Average Change Percent | 0.08085808 |
| Fifty Two Week Change Percent | -72.39264 |
| Fifty Two Week High | 3.53 |
| Fifty Two Week High Change | -3.0715 |
| Fifty Two Week High Change Percent | -0.8701133 |
| Fifty Two Week Low | 0.29 |
| Fifty Two Week Low Change | 0.1685 |
| Fifty Two Week Low Change Percent | 0.58103454 |
| Fifty Two Week Range | 0.29 - 3.53 |
| Financial Currency | AUD |
| First Trade Date Milliseconds | 1,334,842,200,000 |
| Float Shares | 143,034,969 |
| Forward Eps | -0.2 |
| Forward P E | -2.2925 |
| Free Cashflow | -35,678,096 |
| Full Exchange Name | NasdaqGM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -74,779,840 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.000120000004 |
| Held Percent Institutions | 0.024300002 |
| Implied Shares Outstanding | 147,372,131 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.primabiomed.com.au/investor/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,482,883,200 |
| Last Split Factor | 3:10 |
| Long Business Summary | Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia. |
| Long Name | Immutep Limited |
| Market | us_market |
| Market Cap | 67,570,120 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_6701589 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -83,916,456 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 56,886,826 |
| Number Of Analyst Opinions | 1 |
| Open | 0.459 |
| Operating Cashflow | -62,152,988 |
| Operating Margins | -7.63705 |
| Payout Ratio | 0.0 |
| Phone | 61 2 8315 7003 |
| Previous Close | 0.4505 |
| Price Eps Current Year | -1.4328126 |
| Price Hint | 4 |
| Price To Book | 0.9870595 |
| Price To Sales Trailing12 Months | 8.52864 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.907 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.007999986 |
| Regular Market Change Percent | 1.7758017 |
| Regular Market Day High | 0.459 |
| Regular Market Day Low | 0.44 |
| Regular Market Day Range | 0.44 - 0.459 |
| Regular Market Open | 0.459 |
| Regular Market Previous Close | 0.4505 |
| Regular Market Price | 0.4585 |
| Regular Market Time | 1,784,035,910 |
| Regular Market Volume | 38,946 |
| Return On Assets | -0.32099 |
| Return On Equity | -0.61846 |
| Revenue Growth | 0.915 |
| Revenue Per Share | 0.05 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 147,372,131 |
| Shares Percent Shares Out | 0.026400002 |
| Shares Short | 3,897,062 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,346,079 |
| Short Name | Immutep Limited |
| Short Percent Of Float | 0.0272 |
| Short Ratio | 6.56 |
| Source Interval | 15 |
| State | NSW |
| Symbol | IMMP |
| Target High Price | 1.5 |
| Target Low Price | 1.5 |
| Target Mean Price | 1.5 |
| Target Median Price | 1.5 |
| Total Cash | 99,129,496 |
| Total Cash Per Share | 0.673 |
| Total Debt | 1,209,606 |
| Total Revenue | 7,922,731 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.43 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.5789 |
| Two Hundred Day Average Change | -1.1204 |
| Two Hundred Day Average Change Percent | -0.70960796 |
| Type Disp | Equity |
| Volume | 38,946 |
| Website | https://www.immutep.com |
| Zip | 2,000 |